CLINICAL TRIALS PROFILE FOR OLEPTRO
✉ Email this page to a colleague
All Clinical Trials for OLEPTRO
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00253890 ↗ | Insomnia and Drug Relapse Risk | Completed | National Institute on Drug Abuse (NIDA) | Phase 3 | 2005-10-01 | The purposes of this study are: 1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and 2. to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance. |
| NCT00253890 ↗ | Insomnia and Drug Relapse Risk | Completed | Butler Hospital | Phase 3 | 2005-10-01 | The purposes of this study are: 1. to evaluate the relationship between subjective complaints of sleep and objective measures of sleep quality, as measured through polysomnography, and 2. to evaluate the efficacy of trazodone, as compared to placebo, in individuals early in methadone maintenance. |
| NCT00775203 ↗ | A Randomized, Double-blind, Two-arm Study Comparing the Efficacy and Safety of Trazodone Contramid® OAD and Placebo in the Treatment of Unipolar Major Depressive Disorder. | Completed | Labopharm Inc. | Phase 3 | 2007-06-01 | The purpose of this study was to demonstrate efficacy, safety and clinical benefit of Trazodone Contramid® OAD (Once A Day) in the treatment of Unipolar Major Depressive Disorder (MDD). |
| NCT00839072 ↗ | Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers | Completed | Algorithme Pharma Inc | Phase 1 | 2009-02-01 | The objective of the study is to compare the pharmacokinetic profiles of extended-release and immediate-release trazodone formulations |
| NCT00839072 ↗ | Comparative Bioavailability Study of Extended-release and Immediate-release Trazodone in Healthy Adult Volunteers | Completed | Labopharm Inc. | Phase 1 | 2009-02-01 | The objective of the study is to compare the pharmacokinetic profiles of extended-release and immediate-release trazodone formulations |
| NCT01121900 ↗ | A Study to Compare the Bioavailability of 300 mg Trazodone Hydrochloride Extended-release Caplets and 100 mg Trazodone Hydrochloride Immediate-release Tablets (Administered Three Times Daily) | Completed | Labopharm Inc. | Phase 1 | 2008-06-01 | The objective of this study was to compare the pharmacokinetic profiles of the test product, 300 mg trazodone hydrochloride (HCl) extended-release caplets (containing Contramid®), when administered as a single dose, and the reference product, 100 mg trazodone HCl immediate-release tablets (Apotex Corp), when administered three times daily. For this purpose the rate and extent of absorption of trazodone and formation of m-chlorophenylpiperazine (mCPP) after administration of the two formulations, were compared under fasting conditions. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for OLEPTRO
Condition Name
Clinical Trial Locations for OLEPTRO
Trials by Country
Clinical Trial Progress for OLEPTRO
Clinical Trial Phase
Clinical Trial Sponsors for OLEPTRO
Sponsor Name
